MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-20-2026
AbbVie Long-Term Debt 2011-2026 | ABBV
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt AbbVie
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64.5 B | 60.3 B | 52.2 B | 59.1 B | 64.2 B | 77.6 B | 63 B | 35 B | 31 B | 36.4 B | 29.2 B | 10.6 B | 14.3 B | 14.6 B | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 77.6 B | 10.6 B | 43.7 B |
Quarterly Long-Term Debt AbbVie
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 63 B | 63 B | 64.5 B | 58.5 B | 58 B | 63.8 B | 55.6 B | 55.8 B | 59.3 B | 59.1 B | 60.4 B | - | 63.5 B | 64.2 B | 74 B | 74.2 B | 74.2 B | 84.9 B | 77.6 B | 77.6 B | 77.6 B | 67.2 B | 63 B | 63 B | 63 B | 35 B | 35 B | 35 B | 35 B | 31 B | 31 B | 31 B | 31 B | 36.4 B | 36.4 B | 36.4 B | 36.4 B | 29.2 B | 29.2 B | 29.2 B | 29.2 B | 10.5 B | 10.5 B | 10.5 B | 10.6 B | 14.3 B | 14.3 B | 14.3 B | 14.3 B | 14.6 B | 14.6 B | 14.6 B | 14.6 B | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 84.9 B | 10.5 B | 43.6 B |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
273 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
167 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
86 M | - | - | $ 86.2 M | USA |
 |
AlloVir
ALVR
|
1.13 M | - | 4.14 % | $ 49.1 M | USA |
 |
Amgen
AMGN
|
50 B | $ 340.0 | -0.75 % | $ 183 B | USA |
 |
Amneal Pharmaceuticals
AMRX
|
2.57 B | $ 12.32 | -0.24 % | $ 3.86 B | USA |
 |
Applied Molecular Transport
AMTI
|
49 K | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
38 K | - | - | $ 8.42 M | USA |
 |
I-Mab
IMAB
|
68.2 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.42 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
173 M | - | 2.54 % | $ 160 B |  France |
 |
Arcutis Biotherapeutics
ARQT
|
108 M | $ 23.27 | -1.63 % | $ 2.96 B | USA |
 |
Biophytis SA
BPTS
|
1.83 M | - | -13.47 % | $ 169 M | France |
 |
Autolus Therapeutics plc
AUTL
|
66.8 M | $ 1.36 | -2.16 % | $ 362 M |  Britain |
 |
AVROBIO
AVRO
|
188 K | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.33 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
17.5 B | - | - | $ 96.9 B | Britain |
 |
Midatech Pharma plc
MTP
|
4.76 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
278 K | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
962 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alterity Therapeutics Limited
ATHE
|
59.9 K | $ 3.76 | 4.35 % | $ 9.05 B |  Australia |
 |
CymaBay Therapeutics
CBAY
|
467 K | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
8.14 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aytu BioScience
AYTU
|
10.9 M | $ 2.57 | -3.38 % | $ 16.1 M | USA |
 |
Avid Bioservices
CDMO
|
54.2 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
310 K | - | - | $ 1.41 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
175 M | - | - | - |  Russia |
 |
Checkpoint Therapeutics
CKPT
|
2.47 M | - | - | $ 169 M | USA |
 |
Cellectar Biosciences
CLRB
|
309 K | $ 2.75 | 1.48 % | $ 7.17 M | USA |
 |
Aeterna Zentaris
AEZS
|
31 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
2.95 M | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
13.9 M | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
4 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
9.12 M | - | - | $ 26.5 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
47.9 M | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Cyclacel Pharmaceuticals
CYCCP
|
2 K | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
22.4 M | - | - | $ 2.18 B | USA |
 |
Akero Therapeutics
AKRO
|
529 K | - | - | $ 3.67 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
26.4 M | - | - | $ 2.02 B | USA |
 |
CureVac N.V.
CVAC
|
25.4 M | - | - | $ 867 M | Germany |
 |
Dyadic International
DYAI
|
34.6 K | $ 0.88 | 1.66 % | $ 31.8 M | USA |
 |
BioNTech SE
BNTX
|
231 M | $ 89.62 | -1.82 % | $ 27.2 B | Germany |
 |
Coherus BioSciences
CHRS
|
1.46 M | $ 1.67 | - | $ 196 M | USA |
 |
Akouos
AKUS
|
28.3 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
38.2 M | - | - | $ 28.6 M | USA |